Autonomix Medical wins U.S. patent for overactive bladder diagnosis, treatment platform
AMIX•U.S. patent covers bladder diagnosis and treatment platform
- Autonomix Medical received U.S. Patent No. 12,611,134 for devices, systems and methods to diagnose and treat overactive bladder.
- The patent covers a catheter-based platform that maps bladder-wall electrophysiological signals, then delivers targeted therapy with post-treatment verification.
- It also includes an implantable bladder device concept for long-term monitoring, with potential localized drug delivery.
- The company cited an intellectual property portfolio of 112 issued or pending patent applications worldwide, with expirations extending into the late 2030s.
- Autonomix said the technology targets the urology market for overactive bladder, which it estimates affects about 37 million Americans.
